N/A
Manufactured by UCB, Inc.
42,629 FDA adverse event reports analyzed
Last updated: 2026-04-14
MIDAZOLAM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by UCB, Inc.. The most commonly reported adverse reactions for MIDAZOLAM include DRUG INEFFECTIVE, OFF LABEL USE, SEIZURE, HYPOTENSION, DRUG INTERACTION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for MIDAZOLAM.
Out of 24,017 classified reports for MIDAZOLAM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 42,629 FDA FAERS reports that mention MIDAZOLAM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, SEIZURE, HYPOTENSION, DRUG INTERACTION, TOXICITY TO VARIOUS AGENTS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list UCB, Inc. in connection with MIDAZOLAM. Always verify the specific product and NDC with your pharmacist.